Advertisement

Chromatographia

, Volume 81, Issue 11, pp 1503–1517 | Cite as

Analysis of Carbamazepine, Oxcarbazepine, Their Impurities, and Non-Labeled Interfering Substances by Stability-indicating UPLC/MS/MS Method: Studying the Method’s Greenness Profile

  • Maha M. Abdelrahman
  • Nada S. Abdelwahab
Original

Abstract

Carbamazepine (CBZ) and oxcarbazepine (OX) are highly effective anti-psychotic drugs. In USP, it is stated that CBZ has several impurities including, iminodibenzyl (IDB), iminostilbene (IMS), and 9-methylacridine (MA). While, for OX, it is reported to have impurities like, CBZ, IMS and 9-methylacridine (MA). Presence of such impurities in various forms may reduce the efficacy and increase the side effects. It is declared that CBZ (Tegretol®) and OX (Trileptal®) oral suspensions contain methylparaben, propylparaben, and sorbic acid as preservatives. For the first time, CBZ and OX were determined with their impurities and formulation excipients with a highly selective and sensitive ecofriendly LC/MS/MS method using methanol: water containing 0.1% formic acid (95:5, v/v) as a mobile phase. Mass spectrometric quantitation was carried out in positive and negative ion modes. Application of the proposed method to quantify CBZ and OX in their tablets and oral suspensions was successfully done. The results obtained by the suggested method and the reported methods for both drugs agreed well with each other. The developed method has the advantage of being ecofriendly using the simple green mobile phase. Unlike other published methods, it is successfully applied to quantify the impurities and excipients along with parent drugs within limits recommended by USP guidelines.

Graphical Abstract

Keywords

LC/MS/MS Carbamazepine Oxcarbazepine Impurities Formulation excipients Greenness profile 

Notes

Authors’ contributions

Both Dr. MMA and Dr. NSA did the practical work and wrote the manuscript.

Compliance with ethical standards

Conflict of interest

Authors A declares that she has no conflict of interest. Authors B declares that she has no conflict of interest.

Research involving human participants and/or animals

No human volunteers or animals were used in this work.

References

  1. 1.
    Trišović NP, Božić B, Petrović SD, Tadić SJ, Avramov Ivić ML (2014) Electrochemical characterization and determination of carbamazepine as pharmaceutical standard and tablet content on gold electrode. Hem Ind 68:207–212CrossRefGoogle Scholar
  2. 2.
    ”The British Pharmacopoeia” (2007) Her Majesty’s. The Stationary Office, LondonGoogle Scholar
  3. 3.
    ”The United States Pharmacopeia” (2012) National Formulary 35, United States Pharmacopeia Convention Inc., 30th EdGoogle Scholar
  4. 4.
    Mowafy HA, Alanazi FK, El Maghraby GM (2012) Development and validation of an HPLC–UV method for the quantification of carbamazepine in rabbit plasma. Saudi Pharm J 20:29–34CrossRefGoogle Scholar
  5. 5.
    Rodina TA et al. (2016) Rapid HPLC/MS/MS for determination of carbamazepine and carbamazepine-10,11-epoxide. Pharm Chem J 50:52–56CrossRefGoogle Scholar
  6. 6.
    Oh EK, Ban E, Woo JS, Kim CK (2006) Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide in human plasma using high-performance liquid chromatography. Anal Bioanal Chem 386:1931–1936CrossRefGoogle Scholar
  7. 7.
    Elizabeth GS, Darla RL, Mohamed AV, Matthew DK (2007) Simultaneous determination of lamotrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography. Biomed Chromatogr 21:225–228CrossRefGoogle Scholar
  8. 8.
    Budakova L, Brozmanova H, Grundmann M, Fischer J (2008) Simultaneous determination of antiepileptic drugs and their two active metabolites by HPLC. J Sep Sci 31:1–8CrossRefGoogle Scholar
  9. 9.
    Yoshida T, Imai K, Motohashi S, Hamano S, Sato M (2006) Simultaneous determination of zonisamide, carbamazepine, carbamazepine-10,11-epoxide in infant serum by high-performance liquid chromatography. J Pharm Biomed Anal 41:1386–1390CrossRefGoogle Scholar
  10. 10.
    Mennickent S, Fierro R, Vega M, de Diego M, Godoy CG (2009) Instrumental planar chromatographic method for determination of carbamazepine in human serum. J Sep Sci 32:1454–1458CrossRefGoogle Scholar
  11. 11.
    Kadioglu Y, Demirkaya F (2007) Determination of carbamazepine in pharmaceutical dosage form using GC-FID. Chromatographia 66:169–172CrossRefGoogle Scholar
  12. 12.
    Tatar US (2006) Determination of carbamazepine in pharmaceutical preparations using high-performance liquid chromatography and derivative spectrophotometry. Turkish J Pharm Sci 3:123–139Google Scholar
  13. 13.
    Patel RB, Patel MR, Bhatt KK, Patel BG (2011) Development and validation of HPTLC method for estimation of carbamazepine in its formulations and in vitro release study. Chromatogr Res Int 2011:1–8Google Scholar
  14. 14.
    Aydoğmuş Z, Yılmaz EM, Aslan SS, Taş ZE, Üner M (2016) RP-HPLC method for the simultaneous determination of carbamazepine and nilotinib: application to solubility studies. Pharm Chem J 3:1–10Google Scholar
  15. 15.
    Sultana N, Arayne MS, Ali SN (2013) An ultra-sensitive LC method for the simultaneous determination of paracetamol, carbamazepine, losartan and ciprofloxacin in bulk drug, pharmaceutical formulation and human serum by programming the detector. American J Anal Chem 4:24–33CrossRefGoogle Scholar
  16. 16.
    Dzodić PLJ, Zivanović LJ, Protić AD, Zećević ML, Jocić BM (2010) Determination of carbamazepine and its impurities iminostilbene and iminodibenzyl in solid dosage form by column high-performance liquid chromatography. J AOAC Int 93:1059–1068PubMedGoogle Scholar
  17. 17.
    Kumar A, Gupta A, Kumar P, Agarwal AK (2016) Method for optimizing HPLC for separating carbamazepine and its impurities. Int J Res App Nat Soc Sci (IMPACT: IJRANS) 4:63–68Google Scholar
  18. 18.
    Dzˇodic´ P, Zˇivanovic´ L, Protic A, Zecˇevic´ M, Jocic´ B (2009) Chemometrically assisted development and validation of LC for simultaneous determination of carbamazepine and its impurities iminostilbene and iminodibenzyl in solid dosage form. Chromatographia 70:1343–1351CrossRefGoogle Scholar
  19. 19.
    Reddy KS, Naidu NVS (2015) Development and validation of HPLC method for determination of oxcarbazepine in bulk and pharmaceutical formulation. Anal Chem Indian J 15:243–250Google Scholar
  20. 20.
    Bhaumik U et al. (2010) Stability-indicating HPLC method for the determination of oxcarbazepine in pharmaceutical formulation drug and pharmaceutical formulations. Asian J Chem 22:2051–2057Google Scholar
  21. 21.
    Žirojević J, Drljevic-Đurić K, Đurđević A (2014) Determination of oxcarbazepine and its related substances using UHPLC method with UV detection. Arh Farm 64:83–94CrossRefGoogle Scholar
  22. 22.
    Reddy PS, Babu KS, Kumar N (2014) Development and validation of a stability-indicating RP-LC method for the estimation of process-related impurities and degradation products of oxcarbazepine in pharmaceutical formulation. Acta Chromatogr 2:267–282CrossRefGoogle Scholar
  23. 23.
    Pathare DB, Jadhav AS, Shingare MS (2007) Validated stability indicating LC method for oxcarbazepine. J Pharm Biomed Anal 43:1825–1830CrossRefGoogle Scholar
  24. 24.
    Dwivedi P, Yadav S, Rao J (2016) Validated RP HPLC method for the determination of related substance of oxcarbazepine an antiepileptic drugs. Int J PharmTech Res 9:444–451Google Scholar
  25. 25.
  26. 26.
    Juenke JM, Brown PI, Urry FM, McMillin GA (2006) Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC UV. J Chromatogr Sci 44:45–48CrossRefGoogle Scholar
  27. 27.
    Saracino MA, Tallarico K, Raggi MA (2010) Liquid chromatographic analysis of oxcarbazepine and its metabolites in plasma and saliva after a novel micro extraction by packed sorbent procedure. Anal Chim Acta 661:222–228CrossRefGoogle Scholar
  28. 28.
    Kimiskidis V et al. (2007) Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study. J Pharm Biomed Anal 43:763–768CrossRefGoogle Scholar
  29. 29.
    Srinubabu G, Ratnam BV, Rao AA, Rao MN (2008) Development and validation of LC/MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. Chem Pharm Bull 56:28–33CrossRefGoogle Scholar
  30. 30.
    Kashif UH, Kumar N (2014) Development and validation of LC/MS/MS method for the simultaneous quantitative analysis of oxcarbazepine and its metabolite 10-hydroxycarbazepine in K2EDTA plasma. Int J Pharm Pharm Sci 6:422–429Google Scholar
  31. 31.
    Greiner-Sosanko E, Giannoutsos S, Lower DR, Virji MA, Krasowski MD (2007) Drug monitoring simultaneous analysis of lamotrigine, oxcarbazepine, 10- hydroxycarbazepine and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetum. J Chromatogr Sci 45:616–622CrossRefGoogle Scholar
  32. 32.
    Kundu S, Gyadangi B (2013) A simple, validated, single HPLC method for the determination of assay, dissolution, related substance of an antiepileptic drug in different pharmaceutical dosage form. Indo Am J Pharm Res 3:1722–1732Google Scholar
  33. 33.
    Reddy TS, Devi PS (2007) Validation of a high performance thin layer chromatographic method with densitometric detection for quantitative analysis of two anticonvulsants in tablets. J Planar Chromatogr Modern TLC 20:451–456CrossRefGoogle Scholar
  34. 34.
    Rao KS, Belorkar N, Rao MEB (2009) Development and validation of stability indicating liquid chromatographic method for the quantitative determination of oxcarbazepine in tablet dosage forms. Pharm Anal J Young Pharm 1:270–277CrossRefGoogle Scholar
  35. 35.
    Raghavi K, Sindhura M, Prashanthi R, Nalluri BN (2012) Studies on forced degradation of oxcarbazepine using LC-MS compatible stability indicating RP-HPLC method. J Chem Pharm Res 4:3885–3893Google Scholar
  36. 36.
    Bhoite DS, Dhole SN, Bhoir S, Sangole P, Thorat S (2013) Development and validation of stability indicating HPTLC method for determination of oxcarbazepine in bulk and pharmaceutical formulation. Int J Pharm Pharm Sci 5:127–132Google Scholar
  37. 37.
    Fortuna A, Sousa J, Alves G, Falcão A, Soares-da-Silva P (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem 397:1605–1615CrossRefGoogle Scholar
  38. 38.
    Franceschi L, Furlanut M (2005) A simple method to monitor plasma concentration of oxcarbamazepine, carbamazepine, their main metabolites and lamotrignine in epileptic patients. Pharmacol Res 51:297–302CrossRefGoogle Scholar
  39. 39.
    Bugamelli F, Sabbioni C, Mandrioli R, Kenndler E, Albani F, Raggi MA (2002) Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. Anal Chim Acta 472:1–10CrossRefGoogle Scholar
  40. 40.
    Breton H, Cociglio M, Bressolle F, Peyriere H, Blayac JP, Hillaire-Buys D, Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 828: 80–90CrossRefGoogle Scholar
  41. 41.
    Deeb S, McKeown DA, Torrance HJ, Wylie FM, Logan BK, Scott KS (2014) Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC/MS/MS with a focus on their role in forensic cases. J Anal Toxicol 38:485–494CrossRefGoogle Scholar
  42. 42.
    Yin L et al. (2016) Simultaneous determination of ten antiepileptic drugs in human plasma by liquid chromatography and tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in therapeutic drug monitoring. J Sep Sci 9:964–972CrossRefGoogle Scholar
  43. 43.
    Wang L et al. (2016) Simultaneous determination of topiramate, carbamazepine, oxcarbazepine and its major metabolite in human plasma by SFC/ESI/MS/MS with polarity switching: application to therapeutic drug monitoring. Arab J Chem.  https://doi.org/10.1016/j.arabjc.2016.09.016 CrossRefGoogle Scholar
  44. 44.
    Levert H, Odou P, Robert H (2002) Simultaneous determination of four anti-epileptic drugs in serum by high performance liquid chromatography. Biomed Chromatogr 16:19–24CrossRefGoogle Scholar
  45. 45.
    Rowe RC, Sheskey PJ, Owen SC (2006) Handbook of pharmaceutical excipients. 5th ed., Pharmaceutical Press and American Pharmacists AssociationGoogle Scholar
  46. 46.
    Singh S et al. (2012) A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. J Pharm Biomed Anal 69:148–173CrossRefGoogle Scholar
  47. 47.
    Emergency Planning and Community Right-to-Know Act (2004) Section 313; Toxic Release Inventory (TRI)Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmaceutical Chemistry, Faculty of PharmacyNahda University (NUB)Beni-SuefEgypt

Personalised recommendations